

Texas Lung Cancer Conference 2024 Financial Disclosures

Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified financial relationships are thoroughly mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity. These relationships have been mitigated:

Lyudmila Bazhenova reports serving as a consultant/advisory board member for Gilead Sciences, Inc., Teligene, Pfizer, Neuvogen, Bayer, BioAtla, Daiichi, Summit therapeutics, Anheart, Merck, Abbvie, Regeneron, Janssen, Genentech, Novocure, Intervenn Biosciences, Elevation Oncology, ORIC, Mirati, and Turning point.

Sheena Bhalla reports serving as a consultant/advisory board member for Takeda; Mirati; and Merus.

Hossein Borghaei, DO reports receiving grant/research support from BMS, Lilly, and Amgen. He also reports receiving honoraria non-CME from Amgen, Pfizer, Daiichi, and Regeneron. He also serves as a consultant/advisory board member for BMS, Lilly, Genentech, Pfizer, Merck, EMD-Serono, Boehringer Ingelheim, AstraZeneca, Novartis, Genmab, Regeneron, BioNTech, Amgen, Axiom, PharmaMar, Takeda, Mirati, Daiichi, Guardant, Natera, Oncocyte, Beigene, iTEO, Jazz, Janssen, Da Volterra, Puma, BerGenBio, Bayer, and Iobitech. He also reports having non-mutual stock options with Sonnetbio; Inspira; and Nuclei.

Julie Brahmer reports receiving grant/research support from AstraZeneca and BMS. She also serves as a consultant/advisory board member for Amgen, AstraZeneca, Bristol Myers Squibb, Genentech/Roche, Eli Lilly, GlaxoSmithKline, Merck, Sanofi, Regeneron, Janssen, and Johnson & Johnson.

Lauren Averett Byers reports receiving grant/research support from AstraZeneca Pharmaceuticals, Amgen, and Jazz Pharmaceuticals. She is a consultant/advisory board member for Merck Sharp & Dohme Corp., Arrowhead Pharmaceuticals, Chugai Pharmaceutical Co., AstraZeneca Pharmaceuticals, Genentech Inc., BeiGene, AbbVie, Jazz Pharmaceuticals, Puma Biotechnology, Amgen, and Daiichi Sankyo.

Tina Cascone reports receiving grant/research support from MedImmune/AstraZeneca, Bristol Myers Squibb and EMD Serono. She also serves on a speakers bureau/honoraria non-CME for Bristol Myers Squibb and Roche. She also serves as a consultant/advisory board member for MedImmune/AstraZeneca, Bristol Myers Squibb, EMD Serono, Merck, Genentech, Arrowhead Pharmaceuticals, Pfizer Inc. and Regeneron.

Jamie Chaff reports receiving grant/research support from AstraZeneca, BMS, Genentech, Novartis, Merck, and Beigene. She also reports serving as a consultant/advisory board member for AstraZeneca, Arcus biosciences, BMS, Merck, Genentech, Guardant Health, Flame Biosciences, Janssen, and Regeneron.

Terri Conneran reports being the founder/director of KRAS Kickers. She also reports receiving grant/research support from Amgen, AstraZeneca, Mirati, Revolution Medicine, Verastem, Roche Genentech, Lily, and Bayer. She serves on the speakers bureau/honoraria for non-CME for Amgen, Frontier Medicine, Janssen Global, Astra Zenecca, Sanofi, and Bayer. She also serves as a consultant/advisory board member for Novartis, Amgen, Roche, Astra Zenecca, and Mirati.

Alissa Cooper reports being on the speakers bureau/honoraria non-CME for MJH Life Sciences. She also serves as a consultant/advisory board member for Gilead Sciences, Inc.

Ibiayi Dagogo-Jack reports receiving grant/research support from BostonGene, Genentech, Novartis, and Pfizer. She also serves as a consultant/advisory board member for Bristol Myers Squibb, Foundation Medicine, Genentech, Janssen, Merus, Novocure, Pfizer, Sanofi, ThermoFisher Scientific, Roche, and Xcovery.

Davey Daniel reports being an employee/owner at OneOncology. He also reports receiving grant/research support from Eli Lilly, AstraZeneca, ER Quibb, Merck, Takeda, Array, Pfizer, Tera Sera Therapeutic, Abbvie Celgene, Roche, Amgen, Pharmacyclics, Regeneron, and Agios.

Jessica Donington reports serving on a speakers bureau/honoraria for non-CME for AstraZeneca, BMS, Merck, and Roche/Genentech. She also serves as a consultant/advisory board member for Amgen, AstraZeneca, BMS, Merck, and Roche/Genentech.

Alexander Drilion reports receiving grant/research support from Foundation Medicine, Teva, Taiho, GlaxoSmithKlein, and PHarmaMar. He serves on the speakers bureau for 14ner/Elevation Oncology, Amgen, Abbvie, ArcherDX, AstraZeneca, Beigene, BergenBio, Blueprint Medicines, Chugai Pharmaceutical, EcoR1, EMD Serono, Entos, Exelixis, Helsinn, Hengrui Therapeutics, Ignyta/Genentech/Roche, Janssen, Loxo/Bayer/Lilly, Merus, Monopteros, MonteRosa, Novartis, Nuvalent, Pfizer, Prelude, Repair RX, Takeda/Ariad/Millennium, Treeline Bio, TP Therapeutics, Tyra Biosciences, and Verastem. He is a consultant/advisory board member for Bayer, MonteRosa, Abbvie, EcoR1 Capital, LLC, Amgen, Helsinn, Novartis, Lilly Innocare, Boundless Bio, Treeline Bio, Nuvalent, 14ner/Elevation Oncology, Entos, and Prelude. He is a shareholder of mBrace.

Narjust Florez reports serving as a consultant/advisory board member for AstraZeneca, Pfizer, Merck, Regeneron, Mirati, BMS, DSI and Janssen

Patrick Forde reports receiving grant/research support from AstraZeneca, BioNTech, BMS, Novartis, and Regeneron. He also serves as a consultant/advisory board member for Ascendis, AstraZeneca, BMS, Curevac, Novartis, Regeneron, G1, Genelux, Genentech, Gritstone, Merck, Janssen, F Star, Sanofi, Amgen, Fosun, Teva, Synthekine, Flame, Iteos, Tavotek, Teva, and Chromacode.

Shirish M. Gadgeel reports serving as a consultant/advisory board member to Takeda, BMS, Pfizer, Novartis, Merck, Arcus, Gilead Sciences, Inc., GSK, Blueprint, Bayer, Genentech/Roche, Astra-Zeneca, Daiichi-Sankyo, Eli Lilly, Janssen Oncology, and Mirati.

Marina Garassino reports receiving grant/research support from Bristol-Myers Squibb, MSD, Roche/Genentech, AstraZeneca, MedImmune, Pfizer, GlaxoSmithKline, Novartis, Merck, Incyte, Takeda, Spectrum Pharmaceuticals, Blueprint Medicines, Eli Lilly, Ipsen, Janssen, Exelixis, Sanofi, and Amgen. She also reports being on a speakers bureau/honoraria non-CME for MSD Oncology, AstraZeneca, MedImmune, GlaxoSmithKline, Takeda, Roche, Bristol-Myers Squibb, Daiichi Sankyo, Regeneron, Pfizer, Blueprint Pharmaceuticals, Novartis, and Sanofi Aventis. She also serves as a consultant/advisory board member for Bristol-Myers Squibb, MSD, AstraZeneca, Novartis, Takeda, Roche, Sanofi Aventis, Celgene, Daiichi Sankyo, Pfizer, Seattle Genetics, Eli Lilly, GlaxoSmithKline, Bayer Healthcare Pharmaceuticals, Blueprint Medicines, Janssen, Regeneron, Bayer, AbbVie, Mirati, Merck, Boehringer Ingelheim and Blueprint Medicines.

Carl M. Gay reports receiving grant/research support from AstraZeneca. He also serves on a speakers bureau/honoraria for non-CME for AstraZeneca; Beigene; and MJH Healthcare. He also serves as a consultant/advisory board member for AstraZeneca; Bristol Myers Squibb; Catalyst; Daiichi Sankyo; G1 Therapeutics; Jazz Pharmaceuticals; Kisoji Biotechnology; Monte Rosa; and STCube.

Jhanelle Gray reports receiving grant/research support from AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Genentech, G1 Therapeutics, Ludwig Inst of Cancer Research, Merck & Co, Inc, and Pfizer. She also reports serving as a consultant/advisory board member for AbbVie, AstraZeneca, Axion HC Strategies, Blueprint Medicines, Bristol-Myers Squibb, Celgene, Daiichi Sankyo, Inc, EMD Serono, Genentech, Gilead Sciences, Inc, Inivata, Janssen Scientific, Jazz Pharmaceuticals, Loxo Oncology, Merck & Co, Inc, Novartis, Sanofi Pharmaceuticals, Takeda Pharmaceuticals, and Triptych Health Partners.

Balazs Halmos reports receiving grant/research support from Boehringer-Ingelheim, Astra-Zeneca, Merck, BMS, Advaxis, Amgen, AbbVie, Daiichi, Pfizer, GSK, Beigene, and Janssen. He also serves as a consultant/advisory board member for AstraZeneca, Boehringer-Ingelheim, Apollomics, Janssen, Takeda, Merck, Bristol Myers Squibb, Genentech, Pfizer, Eli-Lilly, TPT, Arcus, and Merus.

John V. Heymach reports receiving grant/research support from AstraZeneca, Boehringer-Ingelheim, Spectrum, Mirati, Bristol-Myers Squibb and Takeda. He is a consultant/advisory

board member for Genentech, Mirati Therapeutics, Eli Lilly & Co, Janssen Pharmaceuticals, Boehringer-Ingelheim Pharmaceuticals, Regeneron, Takeda Pharmaceuticals, BerGenBio, Jazz Pharmaceuticals, Curio Science, Novartis, AstraZeneca Pharmaceuticals, BioAlta, Sanofi, Spectrum Pharmaceuticals, GlaxoSmithKline, EMD Serono, BluePrint Medicine, Chugai Pharmaceutical. He is a patent holder with Spectrum.

Wade Iams reports serving as a consultant/advisory board member for Merus, Bristol Myers Squibb, Daiichi Sankyo, Guardant, Tempus, EMD Serono, Amgen, Sanofi, NovoCure, Genentech, AstraZeneca, Catalyt, Elevation Oncology, Jazz Pharma, Janssen, Takeda, Mirati, and G1 Therapeutics.

Melissa Johnson reports receiving grant/research support from Abbvie, Acerta, Adaptimmune, Amgen, Apexigen, Arcus Biosciences, Array BioPharma, Artios Pharma, AstraZeneca, Atreca, BeiGene, BerGenBio, BioAtla, Black Diamond, Boehringer Ingelheim, Bristol Myers Squibb, Calithera Biosciences, Carisma Therapeutics, Checkpoint Therapeutics, City of Hope National Medical Center, Corvus Pharmaceuticals, Curis, CytomX, Daiichi Sankyo, Dracen Pharmaceuticals, Dynavax, Lilly, Elicio Therapeutics, EMD Serono, EQRx, Erasca, Exelixis, Fate Therapeutics, Genentech/Roche, Genmab, Genocea Biosciences, GlaxoSmithKline, Gritstone Oncology, Guardant Health, Harpoon, Helsinn Healthcare SA, Hengrui Therapeutics, Hutchison MediPharma, IDEAYA Biosciences, IGM Biosciences, Immunitas Therapeutics, Immunocore, Incyte, Janssen, Jounce Therapeutics, Kadmon Pharmaceuticals, Kartos Therapeutics, Loxo Oncology, Lycera, Memorial Sloan-Kettering, Merck, Merus, Mirati Therapeutics, Mythic Therapeutics, NeoImmune Tech, Neovia Oncology, Novartis, Numab Therapeutics, Nuvalent, OncoMed Pharmaceuticals, Palleon Pharmaceuticals, Pfizer, PMV Pharmaceuticals, Rain Therapeutics, RasCal Therapeutics, Regeneron Pharmaceuticals, Relay Therapeutics, Revolution Medicines, Ribon Therapeutics, Rubius Therapeutics, Sanofi, Seven and Eight Biopharmaceuticals/Birdie Biopharmaceuticals, Shattuck Labs, Silicon Therapeutics, StemCentRx, Syndax Pharmaceuticals, Takeda Pharmaceuticals, Tarveda, TCR2 Therapeutics, Tempest Therapeutics, Tizona Therapeutics, TMUNITY Therapeutics, Turning Point Therapeutics, University of Michigan, Vyriad, WindMIL Therapeutics, and Y-mAbs Therapeutics. She also serves as a consultant/advisory board member for Abbvie, Amgen, Arcus Biosciences, Arrivent, AstraZeneca, Black Diamond, Boehringer Ingelheim, Calithera Biosciences, Daiichi Sankyo, EcorR1, Genentech/Roche, Genmab, Genocea Biosciences, Gilead Sciences, Inc., GlaxoSmithKline, Gritstone Oncology, Ideaya Biosciences, Immunocore, iTeos, Janssen, Jazz Pharmaceuticals, Merck, Mirati Therapeutics, Molecular Axiom, Normunity, Novartis, Oncorus, Pyramid Biosciences, Regeneron Pharmaceuticals, Revolution Medicines, Sanofi-Aventis, SeaGen, SyntheKine, Takeda Pharmaceuticals, Turning Point Therapeutics, and VBL Therapeutics.

Karen Kelly reports receiving grant/research support from Bristol Myers Squibb, Jounce, Genentech, Abbvie and Novartis. She also reports serving as a consultant/advisory board member for Takeda, Amgen, Genmab, Genentech, AstraZeneca, AbbVie, Janssen, and Sanofi.

Chul Kim reports receiving grant/research support from AstraZeneca, Bristol Myers Squibb, Novartis, Genentech, Janssen, Regeneron, Debiopharm, Karyopharm, Daiichi-Sankyo, Lyell Immunopharma. He serves as a consultant/advisory board member for Novartis, Janssen, AstraZeneca, Sanofi, PierianDx, Diffuse pharmaceuticals, Mirati, Jazz Pharmaceuticals, Arcus Biosciences, Daiichi Sankyo, Eisai, Regeneron.

Kartik Konduri reports serving on a speakers bureau/honoraria non-CME for AstraZeneca, Bristol Myers Squibb and Amgen. He also reports serving as a consultant/advisory board member for EMD Serono, Mirati, Janssen, Regeneron Sanofi, Jazz pharma, Eli Lilly, Bayer, Daiichi Sankyo, Takeda, and Novocure.

Vincent K. Lam reports receiving grant/research support from Bristol Myers Squibb, Merck, SeaGen, and AstraZeneca. He also serves as a consultant/advisory board member for BMS, SeaGen, AstraZeneca, Guardant Health, Takeda, and AnHeart Therapeutics. He also serves as a consultant/advisory board member for Abbvie, Amgen, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Catalyst, Daiichi Sankyo, Eisai, Elevation Oncology, Genentech/Roche, Gilead Sciences, Inc., Guardant Health, Janssen, Jazz Pharmaceuticals, Merck, Merus, Mirati, Novartis, Regeneron, Sanofi, Takeda, and Turning Point Therapeutics.

Xiuning Le reports receiving grant/research support from Eli Lilly, EMD Serono, ArriVent, Teligene, Regeneron, BlackDiamond, and Boehringer Ingelheim. He serves as a consultant/advisory board member for EMD Serono (Merck KGaA), AstraZeneca, Spectrum Pharmaceuticals, Novartis, Eli Lilly, Boehringer Ingelheim, Hengrui Therapeutics, Janssen, Blueprint Medicines, Sensei Biotherapeutics, Abion, and Abbvie.

Ticiana Leal reports receiving grant/research support from Bayer, Pfizer, and Advaxis. She also serves as a consultant/advisory board member for Merck, AstraZeneca, Daiichi-Sankyo, Janssen, Takeda, EMD Serono, Regeron, Eisai, Catalyst, Novocure, Amgen, Roche, Jazz and Pfizer.

Stephen Liu reports receiving grant/research support from Alkermes, Elevation Oncology, Genentech, Gilead Sciences, Inc., Merck, Merus, Nuvalent, RAPT, and Turning Point Therapeutics.

Christine M. Lovly, MD, PhD reports serving as a consultant/advisory board member for Amgen AnHeart, Arrivent, AstraZeneca, Blueprints Medicine, Boehringer Ingelheim, Cepheid D2G, Daiichi Sankyo, EMD Serono Foundation, Medicine Genentech, Indupro, Janssen, Medscape, Novartis, Pfizer, Puma, Roche, and Takeda.

Melina Marmarelis reports receiving grant/research support from Eli Lilly, AstraZeneca, and Genentech. She serves on the speakers bureau/honoraria non-CME for Thermo Fisher. She also serves as a consultant/advisory board member for Janssen, Takeda, Bristol Myers Squibb, Ikena, Bayer, and AstraZeneca. She also reports having Non-Mutual funds Stock Ownership/Stock options with Merck and Janssen.

Eric Nadler reports receiving grant/research support from Genentech, Merck, and Bristol Myers Squibb. He serves on a speakers bureau or receives honoraria for non-CME for Lilly, AstraZeneca, Genentech, Mirati, and Jazz. He serves as a consultant/advisory board member for AstraZeneca and Genentech.

Marcelo Vailati Negro reports receiving grant/research support from Mirati, Novartis, Checkmate, Alaunos, AstraZeneca, Pfizer, Genentech, and Navire. He also serves as a consultant/advisory board member for Mirati, Merck/MSD, Novartis, and Genentech.

Quynh Nguyen reports serving as a consultant/advisory board member for ARS AUE Palliative and Symptom Management.

Raymond Osarogiagbon reports serving on a speakers bureau/honoraria non-CME for AstraZeneca. He also serves as a consultant/advisory board member for American Cancer Society, The Association of Community Cancer Centers, AstraZeneca, Eli Lilly, Genentech/Roche, Triptych Healthcare Partners, Biodesix, Medscape, LUNgevity, The National Cancer Institute, GE Healthcare, and Median Technologies. He also reports having non-mutual funds/stock ownership/stock option with Eli Lilly, Pfizer, Gilead Sciences, Inc., and BridgeBio. He also reports being a patent holder/royalties received from Patents for Lung Cancer Specimen Kit, and Oncobox Device Inc.

Paul Paik reports receiving grant/research support from EMD Serono, Bicara, and Genentech. He also serves as a consultant/advisory board member for Bicara, EMD Serono, Takeda, Janssen, Mirati, and Novartis.

Jyoti Patel reports serving as a consultant/advisory board member for AstraZeneca, AbbVie, Anheart, Blueprint, Gilead Sciences, Inc., Sanofi, Lilly, Daiichi Sankyo, Takeda, and Genentech.

Sandip Patel reports receiving grant/research support from Amgen, AstraZeneca/MedImmune, Bristol Myers Squibb, Eli Lilly, Fate Therapeutics, Gilead Sciences, Inc., Iovance, Merck, Pfizer, Roche/Genentech, and SQZ Biotechnologies. He also reports serving as a consultant/advisory board member for Amgen, AstraZeneca, Bristol Myers Squibb, Certis, Eli Lilly, Jazz, Genentech, Illumina, Merck, Pfizer, Rakuten, and Tempus.

Steve Paulson reports having non-mutual funds/stock ownership/stock options with TG Therapeutics, ADC Therapeutics, Actinium, Bellicum, and Bristol Myers Squibb.

Jason Porter reports serving on a speakers bureau/honoraria non-CME for BMS, AstraZeneca, Jazz, Regen, Mirati, Merck, EMD, Genentech, Amgen, G1, Takeda, Johnson & Johnson, and Guardant. He also serves as a consultant/advisory board member for Amgen, Genentech, Mirati, Pfizer, and Novartis.

Luis Raez reports receiving grant/research support from Bristol Myers Squibb, Genentech, Lilly Oncology, Loxo Pharmaceuticals, Merck, Velos, TG therapeutics, ARCUS, AstraZeneca, and Pfizer.

Joshua Reuss reports receiving grant/research support from Genentech/Roche, Verastem, and Nuvalent. He also reports serving on a speakers bureau/honoraria non-CME for AstraZeneca, and Merck. He also serves as a consultant/advisory board member for Genentech/Roche, Sanofi/Genzyme, Personalis, Guardant, AstraZeneca, BMS, Arcus, Abbvie, Daiichi Sankyo, and Catalyst.

Greg Riely reports receiving grant/research support from Takeda, Pfizer, Roche, Chugai, Genentech, Mirati, Lilly, and Novartis.

Jonathan Riess reports receiving grant/research support from ArriVent, Merck, Novartis, AstraZeneca, Spectrum, Revolution Medicines, IO Biotech, and Kinnate. He also serves as a consultant/advisory board member for Boehringer Ingelheim, Bristol Myers Squibb, Turning Point Roche/Genentech, Biodesix, EMD Serono, Daiichi Sankyo, Blueprint, Novartis, Regeneron, Sanofi, Janssen, Jazz Pharmaceuticals, Bayer, Beigene, Merus NV, and Merck.

Estelamarie Rodriguez reports receiving grant/research support from Gilead Sciences, Inc., Seagen, and Merck. She is also a consultant/advisory board member for Pfizer, Regeneron, Daiichi, and Janssen.

Christian Rolfo, MD, PhD, MBA, Dr. hc. reports receiving grant/research support from Pfizer/LCRF. He also reports serving on a speakers bureau/honoraria for non-CME for AstraZeneca, Roche, Guardant Health, Merck, Sharp & Dohme, COR2ED, Physicians Education Resource, LLC., Intellisphere, LLC, and Boehringer Ingelheim. He also reports serving as a consultants/advisory board member for Archer, Inivata, Bristol Myers Squibb, Novartis, Boston Pharmaceuticals, EMD Serono, AstraZeneca, Roche, Guardant Health, MSD, Pfizer, Mirati, Eisai, COR2ED, Daiichi Sankyo, Sanofi Genzyme- Regeneron, Blueprint, Physicians Education Resource, LLC., Intellisphere, LLC, CEA, Bayer U.C. LLC, General Dynamics, MedStar, Diverse HealthHub, Merck, MH Live Events, Janssen Scientific Affairs, EMD, Amgen, Lungevity, Boehringer, Postgraduate Institute of Medicine, ACC MED, GME, Nadirex, ASCO Plenary Series, Imagene, HMP Education, Medical Educator Consortium, Thermo, and AbbVie.

Julia Rotow reports serving on a speakers bureau or receiving honoraria for non-CME for AstraZeneca.

Joshua Sabari reports receiving grant/research support from Janssen, Mirati, Regeneron, Loxo @Lilly, and Boehringer Ingelheim. He serves as a consultant/advisory board member for AstraZeneca, Abbvie, Genentech, Janssen, Jazz, Loxo Lilly, Mirati, Navire, Pfizer, Regeneron, Sanofi Genzyme, and Takeda.

Rachel E. Sanborn, MD reports receiving grant/research support from AstraZeneca and Merck. She also reports receiving honoraria from Targeted Oncology, EMD Serono, and Illumina. She also serves as a consultant/advisory board member for Janssen Oncology, EMD Serono, Daiichi Sankyo, Sanofi, BeiGene, AstraZeneca, Gilead Sciences, Inc.; Inhibrx, Johnson and Johnson, GSK, Regeneron, G1 Therapeutics, GE HealthCare, Amgen and Lilly Oncology.

Edgardo S. Santos reports serving on a speakers bureau/honoraria non-CME for Amgen, Astrazeneca, Boehringer-Ingelheim, Bristol Myers Squibb, Genentech, Lilly, EMD Serono, G1 Therapeutics, Jazz Pharmaceuticals, Merck, Mirati, Pfizer, Regeneron, Sanofi, Sobi, and Takeda. He also serves as a consultant/advisory board member for Astrazeneca, Abbvie, Genentech, Sanofi, Regeneron, and Novartis.

Stephen Schleicher reports serving on a speakers bureau/honoraria non-CME for Beigene. He also serves as a consultant/advisory board member with Thyme Care. He also has non-mutual funds stock ownership/stock options in Thyme Care, Main Street Health, and OneOncology.

Susan Scott reports receiving grant/research support from Mirati Therapeutics, and Janssen. She also reports serving as a consultant/advisory board member for AstraZeneca, Foundation Medicine, Genentech, Regeneron, and Tempus.

Misty Dawn Shields reports serving on the speakers bureau/honoraria non-CME for Jazz Pharmaceuticals. She also serves as a consultant/advisory board member for Jazz Pharmaceuticals, and AstraZeneca.

Ferdinandos Skoulidis reports receiving grant/research support from Amgen, Revolution Medicines, Mirati Therapeutics, Boehringer Ingelheim, Merck & Co, and Novartis. He also reports serving on a speakers bureau/honoraria non-CME for ESMO, AACR, IASLC, Japanese Lung Cancer Society, Medscape LLC, Intellisphere LLC, VSPO McGill Universite de Montreal, MJH Life Sciences, IDEOlogy Health, MI&T, PER LLC, CURIO LLC, DAVA Oncology, BMS, RV Mais Promocao Eventos LTDS, Amgen, and AstraZeneca. He also serves as a consultant/advisory board member for Amgen Inc, Revolution Medicines, BridgeBio, Beigene, BergenBio, AstraZeneca, Guardant Health Inc., Tango Therapeutics, Novocure, and Calithera Biosciences. He also reports non-mutual funds/stock ownership/stock options with BioNTech SE, and Moderna Inc.

Mark Socinski reports receiving grant/research support from Genentech, Spectrum, Novartis, Beigene, AstraZeneca, Mirati, Daiichi-Sankyo, Pfizer, and Cullinan. He also serves on a speakers bureau/honoraria non-CME for Genentech, AstraZeneca, Lilly, Jazz, Janssen, G1 Therapeutics, Bristol Myers Squibb, Guardant, Sanofi, and Regeneron. He also serves as a consultant/advisory board member with Lilly, Spectrum, Beigene, Mirati, and Genentech.

Brendon Stiles reports receiving grant/research support from BMS Foundation, Bristol Myers Squibb, and ACS. He also serves as a consultant/advisory board member for AstraZeneca,

Pfizer, BMS, Roche/Genentech, Regeneron, Medtronic, Galvanize Therapeutics, Arcus Biosciences, and Merck. He also reports being a patent holder/receiving royalties from ART1 Therapeutic Antibody.

Janet Tu had no relevant financial relationships to report.

Abhirami Vivekanandarajah is the employee/owner for Abhirami Vivekanandarajah/New York cancer and blood specialists. She reports serving on the speakers bureau/honoraria non-CME for AstraZeneca. She also serves as a consultant/advisory board member for Aptitude Health.

Heather Wakelee, MD reports receiving grant/research support from Arrys, Bayer, AstraZeneca, Bristol Myers Squibb, Clovis, Genentech/Roche, Merck, Novartis, Seven, Xcovery, and Helsinn. She also serves as a consultant/advisory board member for Mirati, Merck, Genentech/Roche.

The planners reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity. These relationships have been mitigated:

Amy Gelhorn reports being a shareholder of Tango Therapeutics.

Jennifer Marks, MD reports receiving grant/research support from ASCO/Conquer Cancer Merit Award. She also serves on a speakers bureau/honoraria non-CME for Targeted Healthcare Communications, IDEOlogy Health, IASLC, Curio Sciences, Caris Life Sciences, and Creative Educational Concepts.

The planners at Postgraduate Institute for Medicine (PIM) have no financial relationships to disclose.